Scholar Rock Holding Corporatio SRRK

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
51/100
Moderate

About Scholar Rock Holding Corporatio

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for … Full SRRK analysis →

Competitive advantage assessment

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.74), demonstrating pricing resilience across cycles.
  • Scale Supporting Profitability Profitability at scale is strong (score 0.77), demonstrating competitive advantages.

Key risks

  • ROIC Below WACC or Peers ROIC at 28.8th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
53

Where SRRK ranks in Biotechnology

Scholar Rock Holding Corporatio ranks #228 of 713 scored companies in Biotechnology by moat score — the top 32%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near SRRK in Biotechnology
# Company Moat score Rating
224 Immatics N.V. IMTXW 51/100 Moderate
225 Mineralys Therapeutics, Inc. MLYS 51/100 Moderate
226 Quince Therapeutics, Inc. QNCX 51/100 Moderate
227 Brainstorm Cell Therapeutics In BCLI 51/100 Moderate
228 Scholar Rock Holding Corporatio SRRK 51/100 Moderate
229 Rhythm Pharmaceuticals, Inc. RYTM 51/100 Moderate
230 Seer, Inc. SEER 51/100 Moderate
231 Xilio Therapeutics, Inc. XLO 51/100 Moderate
232 4D Molecular Therapeutics, Inc. FDMT 51/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How SRRK scores on the Corporate Default defenses

Pricing Power

Score 53 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 57 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 56 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 32 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 52 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 61 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SRRK's moat

What is Scholar Rock Holding Corporatio's moat score?

Scholar Rock Holding Corporatio (SRRK) scores 51 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #228 of 713 scored companies in Biotechnology, the top 32%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (61/100) and its weakest is Capital Efficiency (32/100).

How does Scholar Rock Holding Corporatio compare with other Biotechnology companies?

Scholar Rock Holding Corporatio ranks #228 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Brainstorm Cell Therapeutics In (BCLI) at 51 just above it and Rhythm Pharmaceuticals, Inc. (RYTM) at 51 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Scholar Rock Holding Corporatio scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Scholar Rock Holding Corporatio?

The Corporate Default template measures 6 defenses, and SRRK scores: Pricing Power (53), Cost Advantage (57), Customer Stickiness (56), Capital Efficiency (32), Resilience (52), Scale & Market Position (61). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000